Floatz logo

Pd-L1 T-Hank

Merkel Cell Carcinoma

ImmunityBio, Inc.Cell therapyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
81/ 100

Competitive context

45 Active assets in the Merkel Cell Carcinoma cohort.

Asset / SponsorPhaseRating
Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3BB
Cyclophosphamide
Merck Sharp & Dohme LLC
Phase 2/3BB
Atezolizumab
Ariceum Therapeutics GmbH
Phase 2B
Durvalumab
Ariceum Therapeutics GmbH
Phase 2B
Nivolumab
Fred Hutchinson Cancer Center
Phase 2B

View all 50 →

Same molecule, other indications

Pd-L1 T-Hank is also rated in:

Microsatellite InstabilityDormant
CCC
Indicative ·
53 / 100
View asset →
Mismatch Repair DeficiencyDormant
CCC
Indicative ·
53 / 100
View asset →
urothelial carcinomaDormant
CCC
Indicative ·
51 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →